Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi最新文献

{"title":"[CD19-targeted in vivo CAR-T cell therapy for high-risk/refractory B-acute lymphoblastic leukemia: a case report and literature review].","authors":"Y Li, F Y Ma, L H Zhang, J Ren, S B Wang","doi":"10.3760/cma.j.cn121090-20260510-00234","DOIUrl":"10.3760/cma.j.cn121090-20260510-00234","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the safety, pharmacokinetic profile, and preliminary efficacy of a novel lentiviral-based CD19-targeted in vivo chimeric antigen receptor T (CAR-T) cell therapy in a patient with multiply relapsed/refractory B-acute lymphoblastic leukemia (B-ALL) . <b>Methods:</b> A 28-year-old patient with B-ALL at the 920th Hospital of Joint Logistics Support Force, received a single intravenous infusion of a lentiviral-based CD19-targeted in vivo CAR-T product at a dose of 7×10(8) TU. The safety and pharmacokinetic profiles and disease response data were collected and analyzed. Additionally, the outcomes of the current clinical studies on vivo CAR-T cell therapy were reviewed. <b>Results:</b> The patient with high-risk and heavily pretreated B-ALL achieved minimal residual disease negative complete remission by day 16 post infusion, which was sustained until day 50 and enabled subsequent hematopoietic stem cell transplantation. The adverse events mainly consisted of an acute inflammatory reaction within 24 hours after infusion and cytokine release syndrome during the CAR-T expansion phase. Pharmacokinetic monitoring detected peripheral blood CAR-T cells on day 6, with a peak level of 8 629.38 cells/μl on day 14. Literature review suggested that clinical research on in vivo CAR-T cell therapy remains at an early stage, with limited evidence available, and that no prior clinical outcomes of its application in B-ALL patients were reported. <b>Conclusion:</b> CD19-targeted in vivo CAR-T cell therapy demonstrated manageable safety and robust in vivo expansion in our patient, enabling rapid remission and creating a critical window for transplantation. Our case preliminarily supports the feasibility and potential clinical value of in vivo CAR-T cell therapy in high-risk, heavily pretreated B-ALL patients and provides a valuable practical reference for clinical application.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 8","pages":"771-776"},"PeriodicalIF":0.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on the diagnosis and treatment of pulmonary chronic graft-versus-host disease (2026)].","authors":"","doi":"10.3760/cma.j.cn121090-20260520-00254","DOIUrl":"10.3760/cma.j.cn121090-20260520-00254","url":null,"abstract":"<p><p>Pulmonary chronic graft-versus-host disease (cGVHD) is a clinically significant complication after allogeneic hematopoietic stem cell transplantation, severely affecting the quality of life and survival rate of hematopoietic stem cell transplantation recipients. Bronchiolitis obliterans syndrome and interstitial lung diseases are the two main clinical entities. However, the insidious onset, diagnostic challenges, and limited therapeutic options of pulmonary cGVHD result in suboptimal clinical management and poor prognosis. Based on the latest developments in pulmonary cGVHD research and increasing evidence-based medicine data, this consensus was developed collaboratively by multidisciplinary experts domestically, providing recommendations for the early recognition, diagnosis, treatment, and management of pulmonary cGVHD, aiming to establish a standardized diagnostic and therapeutic workflow for pulmonary cGVHD applicable to clinical practice in China, to better guide clinical practice and improve patients' quality of life and survival rate.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 8","pages":"721-738"},"PeriodicalIF":0.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Mutation characteristics and prognosis of SF3B1-mutated myeloid neoplasms: an analysis of 183 patients].","authors":"H M Zhang, N Wu, A R Jiang, J D Xie, H Yao, Q Wang, D D Liu, J L Pan, Z X Chen, S N Chen, H J Shen","doi":"10.3760/cma.j.cn121090-20260303-00116","DOIUrl":"10.3760/cma.j.cn121090-20260303-00116","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the mutational characteristics and prognosis of patients with myeloid neoplasms and SF3B1 mutations. <b>Methods:</b> This retrospective cohort study analyzed clinical data from 183 patients with myeloid neoplasms and SF3B1 mutations diagnosed at the First Affiliated Hospital of Soochow University from October 2016 to December 2024. High-throughput sequencing was used to detect mutations in 52 common genes associated with myeloid neoplasms, and the patients' mutational characteristics were examined. <b>Results:</b> A total of 31 types of SF3B1 mutations were detected in the present study. SF3B1 mutations mainly occurred within the HEAT domain, spanning amino acids 581 to 933. The median number of gene mutations in patients with myelodysplastic neoplasms (MDS) [2 (1-7) ] was lower than that in patients with SF3B1-mutated myelodysplastic/myeloproliferative neoplasms (MDS/MPN) [4 (1-9) ] and acute myeloid leukemia (AML) [3 (1-9) ], with all differences being significant (all <i>P</i><0.001). Among patients with clonal hematopoiesis and MDS with <5% blasts, those with an SF3B1 mutational variant allele frequency (VAF) of <10% had higher median HGB levels than those with an SF3B1 mutation VAF of ≥10% (95 g/L <i>vs</i> 76 g/L, <i>P</i>=0.002). Patients with an SF3B1 mutation VAF of <10% had a lower median percentage of ring sideroblasts than those with an SF3B1 mutation VAF of ≥10% (3% <i>vs</i> 41%, <i>P</i><0.001). Furthermore, the incidence of JAK2 V617F mutations was higher in the MDS/MPN patients than in the MDS patients (22.2% <i>vs</i> 1.2%, <i>P</i>=0.001), as was the incidence of RUNX1 mutations (33.3% <i>vs</i> 6.6%, <i>P</i>=0.002). The incidence of RUNX1 mutation was higher in AML patients than in MDS patients (24.2% <i>vs</i> 6.6%, <i>P</i>=0.008), as was the RAS family gene mutations (66.7% <i>vs</i> 3.8%, <i>P</i><0.001). In MDS and MDS/MPN, patients with RUNX1 mutations had a higher risk of progression to AML than those without such a mutation (<i>P</i><0.001). Patients with MDS-SF3B1 (91.6%) and MDS/MPN (79.9%) demonstrated better 5-year overall survival than those with AML (63.8%) (<i>P</i>< 0.001 and <i>P</i>=0.033, respectively). <b>Conclusion:</b> Patients with different subtypes of SF3B1-mutated myeloid neoplasms exhibit distinct mutational profiles and prognoses.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 8","pages":"785-791"},"PeriodicalIF":0.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Impact of non-donor specific HLA antibodies on outcomes of allogeneic hematopoietic stem cell transplantation].","authors":"J N Yang, H Xiao, X Li","doi":"10.3760/cma.j.cn121090-20251218-00601","DOIUrl":"10.3760/cma.j.cn121090-20251218-00601","url":null,"abstract":"<p><p>We retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) and completed anti-HLA antibody screening at our center between January 2016 to July 2025 to examine the impact of non-donor specific HLA antibodies (NDSA) on the clinical outcomes in this patient population and to analyze the potential efficacy of using desensitization therapies. Among the 618 patients screened patients, 379 underwent allo-HSCT. Fifty-five patients were NDSA-positive. Based on the screening results, NDSA-positive patients were divided into the following groups according to the mean fluorescence intensity (MFI) : 1 000≤MFI<10,000 and MFI≥10,000 groups. Compared with the antibody-negative group, the NDSA-positive patients were older, more likely to be female, and had a higher rate of prior pregnancy (<i>P</i><0.05). In the fully matched transplants without desensitization, the 3-year overall survival (OS) was significantly lower in the NDSA-positive group (<i>P</i>=0.043). Stratified analysis showed that NDSA MFI of ≥10,000 was as an independent risk factor for inferior 3-year OS (<i>HR</i>=4.364, 95% <i>CI</i>: 1.041-18.291, <i>P</i><0.05) and event-free survival (EFS) (<i>HR</i>=3.453, 95% <i>CI</i>: 1.035-11.518, <i>P</i><0.05). In the propensity score-matched NDSA-positive cohort, the desensitization group showed numerically higher 3-year OS[100% <i>vs</i> (66.7±15.7) %, <i>P</i>=0.123] and EFS[ (83.3±15.2) % <i>vs</i> (53.3±17.3) %, <i>P</i>=0.253] than the untreated group. Our study findings suggest that NDSA MFI of ≥10,000 may be associated with poorer long-term survival in patients receiving fully matched allo-HSCT. Desensitization therapy may improve the long-term outcomes of these patients.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 8","pages":"796-800"},"PeriodicalIF":0.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The impact of collateral CMV-seropositive and CMV-seronegative donors on the outcomes of allogeneic hematopoietic stem cell transplantation].","authors":"J Liu, Y Y Zhang, X D Mo, Y Q Sun, M Lyu, X Y Pei, X S Zhao, Y F Cheng, H X Fu, L P Xu, X H Zhang, X J Huang, Y Wang","doi":"10.3760/cma.j.cn121090-20251016-00470","DOIUrl":"10.3760/cma.j.cn121090-20251016-00470","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the impact of collateral cytomegalovirus (CMV) -positive versus CMV-negative donors on the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) . &lt;b&gt;Method:&lt;/b&gt; This retrospective cohort study analyzed CMV-related events and survival outcomes in allo-HSCT recipients with CMV seropositive who received grafts from CMV-negative (CMV-negative donor group) or collateral CMV-positive (collateral CMV-positive donor group) haploidentical donors at Peking University People's Hospital from January 2017 to March 2025. &lt;b&gt;Results:&lt;/b&gt; A total of 126 patients were enrolled, including 16 CMV-negative and 58 collateral CMV-positive donors before the availability of letermovir, and 27 CMV-negative and 25 collateral CMV-positive donors after the availability of letermovir. With a median follow-up of 1 091 (660, 1 536) days, before the availability of letermovir in China, the CMV-negative donor group had a significantly higher incidence of refractory CMV viremia (87.5% &lt;i&gt;vs&lt;/i&gt; 50.0%, &lt;i&gt;P&lt;/i&gt;=0.007) and a longer median duration of first CMV viremia [29 (95% &lt;i&gt;CI&lt;/i&gt;: 25-33) &lt;i&gt;vs&lt;/i&gt; 17 (95% &lt;i&gt;CI&lt;/i&gt;: 15-19) days, &lt;i&gt;P&lt;/i&gt;=0.004] than the collateral CMV-positive donor group. The use of letermovir significantly delayed the onset of first post-transplant CMV viremia in both groups: from day 37 (95% &lt;i&gt;CI&lt;/i&gt;: 31-43) to day 140 (95%&lt;i&gt;CI&lt;/i&gt;: 136-144) in the CMV-negative donor group (&lt;i&gt;P&lt;/i&gt;&lt;0.001) and from day 36 (95% &lt;i&gt;CI&lt;/i&gt;: 33-39) to day 111 (95% &lt;i&gt;CI&lt;/i&gt;: 76-146) in the collateral CMV-positive donor group (&lt;i&gt;P&lt;/i&gt;=0.013). With letermovir prophylaxis, the difference in the median duration of the first CMV viremia between the CMV-negative and collateral CMV-positive donor groups was no longer significant [18 (95% &lt;i&gt;CI&lt;/i&gt;: 17-19) &lt;i&gt;vs&lt;/i&gt; 12 (95%&lt;i&gt;CI&lt;/i&gt;: 0-25) days, &lt;i&gt;P&lt;/i&gt;=0.313]. Letermovir reduced the incidence of refractory CMV viremia in the CMV-negative donor group (40.7% &lt;i&gt;vs&lt;/i&gt; 87.5%, &lt;i&gt;P&lt;/i&gt;=0.003), but the incidence remained higher than that in the collateral CMV-positive donor group (40.7% &lt;i&gt;vs&lt;/i&gt; 12.0%, &lt;i&gt;P&lt;/i&gt;=0.020). Regardless of letermovir use, there were no statistically significant differences in the 3-year overall survival, non-relapse mortality, or cumulative relapse rate between the CMV-negative and collateral CMV-positive donor groups (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). Multivariate analysis showed that CMV disease was an independent risk factor for overall survival (&lt;i&gt;HR&lt;/i&gt;=3.0, 95%&lt;i&gt;CI&lt;/i&gt;: 1.3-7.3, &lt;i&gt;P&lt;/i&gt;=0.014) and non-relapse mortality (&lt;i&gt;HR&lt;/i&gt;=3.1, 95%&lt;i&gt;CI&lt;/i&gt;: 1.1-8.8, &lt;i&gt;P&lt;/i&gt;=0.035). Refractory CMV viremia was an independent risk factor for CMV disease (&lt;i&gt;HR&lt;/i&gt;=12.0, 95%&lt;i&gt;CI&lt;/i&gt;: 2.9-50.7, &lt;i&gt;P&lt;/i&gt;=0.001). Logistic regression analysis showed that having a CMV-negative donor status without letermovir prophylaxis was an independent risk factor for refractory CMV viremia (&lt;i&gt;P&lt;/i&gt;=0.005) . &lt;b&gt;Conclusion:&lt;/b&gt; CMV-negative donors increase the risk of CMV-related ","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 8","pages":"761-770"},"PeriodicalIF":0.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of treatment outcomes of acute myeloid leukemia between different genders].","authors":"Z R Li, L Yu, L J Hu, Y Wei, W B Duan, T Zhao, Q Fu, H Jiang, F F Tang, J Wang, J S Jia, Y Q Sun, X D Mo, L P Xu, Y Wang, X H Zhang, X J Huang, Q Jiang","doi":"10.3760/cma.j.cn121090-20260312-00129","DOIUrl":"10.3760/cma.j.cn121090-20260312-00129","url":null,"abstract":"<p><p><b>Objective:</b> To compare the treatment outcomes between male and female patients with acute myeloid leukemia (AML) . <b>Methods:</b> In this retrospective cohort study, data from adult patients with newly diagnosed AML at Peking University People's Hospital between January 2017 and June 2025 were collected and analyzed. The primary outcomes included complete remission with or without incomplete hematological recovery (CR/CRi) and overall survival (OS) rate. <b>Results:</b> A total of 2 264 patients were enrolled, including 1 180 males (52%). Males had significantly higher hemoglobin, uric acid, and albumin levels, but a lower estimated glomerular filtration rate than females (<i>P</i>=0.006 for albumin, <i>P</i><0.001 for other variables). Males harbored a greater number of myeloid gene mutations (<i>P</i>=0.001) and showed significantly higher frequencies of ASXL1, U2AF1, SRSF2, RUNX1, ZRSR2, DDX41, SETBP1, TET2, and FLT3-TKD mutations, as well as -7/7q- and +8 chromosomal abnormalities. Contrarily, males exhibited significantly lower frequencies of NPM1, DNMT3A, and FLT3-ITD mutations than females. Multivariate analysis showed that male sex was significantly associated with a lower rate of CR/CRi after one course of induction therapy (<i>OR</i>=0.80, 95% <i>CI</i>: 0.66-0.97, <i>P</i>=0.023) and inferior relapse-free survival (<i>HR</i>=1.17, 95% <i>CI</i>: 1.00-1.37, <i>P</i>=0.046) and OS (<i>HR</i>=1.27, 95% <i>CI</i>: 1.09-1.47, <i>P</i>=0.002). Among patients classified as having favorable-, intermediate-, or adverse-risk disease according to ELN 2022 risk classification, males had inferior OS compared with females. In patients receiving the azacitidine plus venetoclax regimen, males had a significantly lower CR/CRi rate after one treatment course (62% <i>vs</i> 73%, <i>P</i>=0.004), but the difference was not significant in those receiving intensive chemotherapy (70% <i>vs</i> 71%, <i>P</i>=0.593) or the CAG regimen (54% <i>vs</i> 62%, <i>P</i>=0.222). Among patients who achieved CR/CRi, the 4-year OS rate was significantly lower in males than in females in both the allogeneic hematopoietic stem cell transplantation (allo-HSCT) group with CR₁ [74% (95% <i>CI</i>: 69%-78%) <i>vs</i> 81% (95% <i>CI</i>: 77%-85%), <i>P</i>=0.007] and allo-HSCT group with CR₂ or no response [54% (95% <i>CI</i>: 43%-66%) <i>vs</i> 69% (95% <i>CI</i>: 58%-80%), <i>P</i>=0.035]. In the non-transplant group, males showed a trend toward inferior 4-year OS rate[55% (95% <i>CI</i>: 49%-60%) <i>vs</i> 59% (95% <i>CI</i>: 54%-64%), <i>P</i>=0.084]. <b>Conclusion:</b> In patients with AML, males are more likely to harbor myelodysplasia-related gene mutations and chromosomal abnormalities, and sex-based disparities in the treatment response and OS rates have also been observed.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 8","pages":"739-747"},"PeriodicalIF":0.0,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advances in single cell omics applications in mantle cell lymphoma].","authors":"C Wang, Q Zhang, X Cao","doi":"10.3760/cma.j.cn121090-20260317-00135","DOIUrl":"10.3760/cma.j.cn121090-20260317-00135","url":null,"abstract":"<p><p>Mantle cell lymphoma (MCL) is a mature B-cell neoplasm characterized by marked biological and clinical heterogeneity. Although novel strategies such as Bruton's tyrosine kinase inhibitors and chimeric antigen receptor T-cell therapy have improved outcomes for a subset of patients, primary resistance, early relapse, and post-treatment progression remain major challenges in clinical management. Conventional bulk-level assays have limited capacity to resolve subclonal architecture, cellular state transitions, and microenvironmental remodeling of MCL. The development of single-cell omics and its derived spatially resolved technologies now enables the profiling of clonal evolution, immune ecology, and resistance-associated programs of MCL at both cellular and spatial dimensions. This review summarizes recent advances in the application of single-cell RNA sequencing, single-cell B/T-cell receptor sequencing, single-cell DNA sequencing, single-cell epigenomics, multimodal profiling, and spatial transcriptomic/imaging approaches to MCL. We focus on their contributions to the understanding of intratumoral heterogeneity, immune microenvironmental remodeling, therapeutic resistance, and potential clinical translation, as well as current challenges.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"714-718"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Wiskott-Aldrich syndrome with follicular lymphoma: a case report].","authors":"Y Zhang, Y Zhang, Q Y Chen, S J Wang, M H Duan, W Zhang","doi":"10.3760/cma.j.cn121090-20251204-00568","DOIUrl":"10.3760/cma.j.cn121090-20251204-00568","url":null,"abstract":"","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"708"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The causes of death in elderly patients undergoing haploidentical stem cell transplantation].","authors":"W Zhao, R Ma, X Y Luo, W Sun, W Han, X D Mo, Y Wang, X H Zhang, L P Xu, X J Huang, Y Q Sun","doi":"10.3760/cma.j.cn121090-20260125-00057","DOIUrl":"10.3760/cma.j.cn121090-20260125-00057","url":null,"abstract":"<p><p><b>Objective:</b> To analyze the causes of death in elderly patients after haploidentical stem cell transplantation (haplo-HSCT) . <b>Method:</b> This single-center retrospective cohort study included 404 patients aged >55 years who underwent haplo-HSCT at Peking University People's Hospital between January 3, 2019, and December 14, 2023, and analyzed the causes of death among those who died. <b>Results:</b> The last follow-up was October 11, 2025, with a median follow-up duration of 708 (12-2 343) days. A total of 139 patients died after transplantation, with a mortality rate of 34.4%. Relapse was the leading cause of death (40.3%), followed by infection (33.8%) and graft-versus-host-disease (11.5%). Subgroup analysis revealed that relapse was the primary cause of death in patients with myeloid malignancies, whereas infection was most common in those with lymphoid malignancies. Patients in non-remission and those with minimal residual disease-positive status exhibited higher relapse death rates, representing the predominant cause of death. Factors such as patient age, HCT-CI, donor-specific antibody status, conditioning regimens, stem cell source, and post-transplantation phases did not significantly influence the causes of death. <b>Conclusion:</b> Relapse and infection remain the primary causes of death in older patients following haplo-HSCT.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"649-655"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575520/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Exploring the feasibility and limitations of using large language model to interpret bibliometric findings: a case study in hemophilia gene therapy].","authors":"Y Bai, H W Bo, F Xue, Y Wang, J Zhang, Z Song","doi":"10.3760/cma.j.cn121090-20260122-00046","DOIUrl":"10.3760/cma.j.cn121090-20260122-00046","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To evaluate the feasibility and limitations of using a large language model to assist in the interpretation of bibliometric findings. &lt;b&gt;Methods:&lt;/b&gt; This study retrieved 1599 English-language articles on hemophilia gene therapy published between 1970 and 2024 from the Web of Science Core Collection, comprising 1019 articles from the United States, 174 from China, and 172 from the United Kingdom. VOSviewer was used for keyword co-occurrence and clustering analyses of the global and country-specific datasets, whereas CiteSpace was used for keyword co-occurrence, clustering, and burst-detection analyses of the global dataset. Structured data exported from the two tools were interpreted with DeepSeek-R1-0528 to summarize research hotspots and their temporal evolution. Two domain experts independently interpreted the global data and reviewed the country-specific interpretations generated using DeepSeek. Additional literature searches on CRISPR/Cas9, stem-cell-based approaches, and in utero gene therapy were conducted to cross-validate the national research characteristics inferred by the model. &lt;b&gt;Results:&lt;/b&gt; DeepSeek summarized global hemophilia gene therapy research into four major themes: the design and in vivo expression regulation of gene therapy vectors; Adeno-associated virus vector delivery strategies and breakthroughs in immunogenicity; the clinical translation and real-world application of gene therapy; the mechanisms of immune tolerance induction and inhibitor formation. Based on seven major CiteSpace clusters and the temporal and burst information of the keywords, DeepSeek further outlined four stages of development: early exploration of vectors and animal models, optimization of delivery and therapeutic strategies, clinical validation, and increasing attention to clinical application and patient benefits. The core research themes and overall developmental trajectory for the global dataset identified using DeepSeek were broadly consistent with expert interpretations, and the model rapidly generated well-structured summaries. However, expert calibration remained necessary for professional terminology, stage delineation, and historical milestone recognition. In country-specific datasets, DeepSeek demonstrated risks of conceptual conflation, overgeneralization of emerging research directions, and inappropriate cross-country comparisons according to within-country keyword frequencies or cluster strengths. Additional searches revealed that the relative prominence or absence of a keyword within a national dataset could not be directly interpreted as international leadership or a lack of research activity. &lt;b&gt;Conclusions:&lt;/b&gt; Large language models can assist in interpreting global bibliometric findings and improve the efficiency of identifying research hotspots and outlining developmental trajectories; however, they cannot replace domain experts. Interpretations of emerging research directions and cross-country differenc","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"684-693"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}